[1]CHEN X,KOU L,XIE X,et al.Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma[J].Immunology,2024,172(1):21-45.
[2]刘宗超,李哲轩,张阳,等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(02):1-14.
LIU ZC,LI ZX,ZHANG Y,et al.Interpretation of 2020 global cancer statistics report[J].Journal of Integrated Cancer Therapy Electronic,2021,7(02):1-14.
[3]CHEN H,CHEN J,YUAN H,et al.Hypoxia-inducible factor-1α:A critical target for inhibiting the metastasis of hepatocellular carcinoma[J].Oncology Letters,2022,24(2):284.
[4]CHEN Z,HAN F,DU Y,et al.Hypoxic microenvironment in cancer:molecular mechanisms and therapeutic interventions[J].Signal Transduct Target Ther,2023,8(1):70.
[5]COWMAN SJ,KOH MY.Revisiting the HIF switch in the tumor and its immune microenvironment[J].Trends Cancer,2022,8(1):28-42.
[6]林小钦,熊克宫,刘邦,等.竹节香附素A对HepG2细胞缺氧诱导因子-1α基因和蛋白表达的影响[J].现代肿瘤医学,2017,25(15):2369-2372.
LIN XQ,XIONG KG,LIU B,et al.Raddeanin A on HepG2 cells and the expression of hypoxia-inducible factor-1 alpha gene and protein in vitro[J].Modern Oncology,2017,25(15):2369-2372.
[7]CHU Q,GU X,ZHANG Q,et al.Regulatory mechanism of HIF-1α and its role in liver diseases:a narrative review[J].Ann Transl Med,2022,10(2):109.
[8]WANG R,ZHU H,YANG M,et al.DNA methylation profiling analysis identifies a DNA methylation signature for predicting prognosis and recurrence of lung adenocarcinoma[J].Oncol Lett,2019,18(6):5831-5842.
[9]QU Y,LU J,MEI W,et al.Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network[J].Transl Cancer Res,2022,11(11):4019-4036.
[10]COPELAND SJ,MCRAE A,GUARGUAGLINI G,et al.Actin-dependent regulation of cilia length by the inverted formin FHDC1[J].Mol Biol Cell,2018,29(13):1611-1627.
[11]TONG CS,SU M,SUN H,et al.Collective dynamics of actin and microtubule and its crosstalk mediated by FHDC1[J].Front Cell Dev Biol,2024,11:1261117.
[12]KATOH M,KATOH M.Identification and characterization of human FHDC1,mouse Fhdc1 and zebrafish fhdc1 genes in silico[J].Int J Mol Med,2004,13(6):929-934.
[13]WANG S,WANG Y,LU J,et al.LncRNA LINC00665 promotes ovarian cancer cell proliferation and inhibits apoptosis via targeting miR-181a-5p/FHDC[J].Appl Biochem Biotechnol,2022,194(9):3819-3832.
[14]LI XL,ZHU XD,CAI H,et al.Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma:A propensity score matching analysis[J].Surgery,2019,165(6):1161-1167.
[15]BAO Q,ZENG Y,LOU Q,et al.Clinical significance of RNA methylation in hepatocellular carcinoma[J].Cell Commun Signal,2024,22(1):204.
[16]HAO X,SUN G,ZHANG Y,et al.Targeting immune cells in the tumor microenvironment of HCC:New opportunities and challenges[J].Front Cell Dev Biol,2021,9:775462.
[17]GUPTA T,JARPULA NS.Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status[J].World J Hepatol,2024,16(3):353-365.
[18]MINTON K.Enhancing antitumour eosinophils[J].Nat Rev Immunol,2019,19(4):202-203.
[19]ORSI G,TOVOLI F,DADDUZIO V,et al.Prognostic role of blood eosinophil count in patients with sorafenib-treated hepatocellular carcinoma[J].Target Oncol,2020,15(6):773-785.
[20]BIAN Z,GONG Y,HUANG T,et al.Deciphering human macrophage development at single-cell resolution[J].Nature,2020,582(7813):571-576.
[21]程叶,蒯晴叶,张艳,等.TAM在肿瘤免疫治疗中的研究进展[J/OL].肿瘤:1-11[2023-10-20].http://kns.cnki.net/kcms/detail/31.1372.R.20230901.0848.002.html.DOI:10.3781/j.issn.1000-7431.2023.2209-0609.
CHENG Y,KUAI QY,ZHANG Y,et al.Research progress of TAM in tumor immunotherapy[J/OL].Tumor: 1-11[2023-10-20].http://kns.cnki.net/kcms/detail/31.1372.R.20230901.0848.002.html.DOI:10.3781/j.issn.1000-7431.2023.2209-0609.
[22]王方园,孔宪斌,杨玉莹,等.M2型TAMs激活NF-κB通路促进结肠癌细胞侵袭转移的实验研究[J].现代肿瘤医学,2020,28(21):3651-3656.
WANG FY,KONG XB,YANG YY,et al.The experimental study of M2 TAMs activating NF-κB pathway to promote the invasion and metastasis of colon cancer cells[J].Modern Oncology,2020,28(21):3651-3656.
[23]ZHANG H,DAI Z,WU W,et al.Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer[J].J Exp Clin Cancer Res,2021,40(1):184.
[24]PESSION G,SCOTTI C,MAGGI M,et al.Hepatocellular carcinoma:Old and emerging therapeutic targets[J].Cancers(Basel),2024,16(5):901.
[25]CUI JW,LI Y,YANG Y,et al.Tumor immunotherapy resistance:Revealing the mechanism of PD-1/PD-L1-mediated tumor immune escape[J].Biomed Pharmacother,2024,171:116203.